AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31076215 — intervention group
Group type: COMPARATOR
Intervention: Simplified Psychoeducation (Control)
Number of subjects: 129
Study 28742103 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (teachers trained to educate on HIV/AIDS)
Number of subjects: 1381
Study 25793988 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 26
Study 25793988 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 23675796 — intervention group
Group type: EXPERIMENTAL
Intervention: SNAPPS group
Number of subjects: 38
Study 23675796 — intervention group
Group type: COMPARATOR
Intervention: Usual and customary group
Number of subjects: 38
Study 21327728 — intervention group
Group type: EXPERIMENTAL
Intervention: Transtympanic steroid injections (Group A)
Number of subjects: 46
Study 21327728 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of steroids (Group B)
Number of subjects: 46
Study 19844853 — intervention group
Group type: EXPERIMENTAL
Intervention: New therapeutic developments in lung cancer management
Number of subjects: 0
Study 16489524 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (very-point technique)
Number of subjects: 23
Study 16489524 — intervention group
Group type: COMPARATOR
Intervention: Sham laser treatment (placebo)
Number of subjects: 23
Study 12724245 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-directive counselling
Number of subjects: 193
Study 12724245 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy
Number of subjects: 193
Study 12724245 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychodynamic therapy
Number of subjects: 193
Study 12724245 — intervention group
Group type: COMPARATOR
Intervention: Routine primary care
Number of subjects: 193
Study 10647539 — intervention group
Group type: EXPERIMENTAL
Intervention: DRINK (oral rehydration, 0.45% NaCl)
Number of subjects: 8
Study 10647539 — intervention group
Group type: EXPERIMENTAL
Intervention: IV (intravenous rehydration, 0.45% NaCl)
Number of subjects: 8
Study 10647539 — intervention group
Group type: COMPARATOR
Intervention: CONTROL (no fluid)
Number of subjects: 8
Study 10647539 — intervention group
Group type: EXPERIMENTAL
Intervention: IV
Number of subjects: 8
Study 10647539 — intervention group
Group type: EXPERIMENTAL
Intervention: DRINK
Number of subjects: 8
Study 10647539 — intervention group
Group type: COMPARATOR
Intervention: CONTROL
Number of subjects: 8
Study 7537488 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfuzosin 2.5 mg tid
Number of subjects: 63
Study 7537488 — intervention group
Group type: COMPARATOR
Intervention: Serenoa repens 160 mg bid
Number of subjects: 63
Study 1963273 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirarubicin (THP) at 55 mg/m2, Etoposide at 100 mg/m2 (days 1-3), Vincristine at 2 mg (day 1)
Number of subjects: 20
Study 1963273 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirarubicin (THP) at 60 mg/m2
Number of subjects: 20
Study 1963273 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirarubicin (THP) at 40 mg/m2, 50 mg/m2, and 55 mg/m2
Number of subjects: 20
Study 1963273 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirarubicin (THP) at 55 mg/m2
Number of subjects: 20
Study 31380689 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals whose partner participated in the study
Number of subjects: 1294
Study 31380689 — intervention group
Group type: COMPARATOR
Intervention: Individuals whose partner did not participate
Number of subjects: 1294
Study 31380689 — intervention group
Group type: COMPARATOR
Intervention: Individuals who participated alone despite being asked to invite their partner
Number of subjects: 1294
Study 28801880 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational Intervention (EI)
Number of subjects: 133
Study 28801880 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 133
Study 28274672 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography (LDCT) screening
Number of subjects: 1589
Study 26978767 — intervention group
Group type: EXPERIMENTAL
Intervention: Single laparoscopic access
Number of subjects: 95
Study 26978767 — intervention group
Group type: COMPARATOR
Intervention: Multiport laparoscopic-assisted technique
Number of subjects: 95
Study 23706051 — intervention group
Group type: EXPERIMENTAL
Intervention: ITPR device with -5 mm Hg endotracheal tube pressure
Number of subjects: 10
Study 23706051 — intervention group
Group type: EXPERIMENTAL
Intervention: ITPR device with -9 mm Hg endotracheal tube pressure
Number of subjects: 10
Study 21385788 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction (25% CR)
Number of subjects: 77
Study 19632695 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-restricted diet (CRD)
Number of subjects: 40
Study 19632695 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet (LFD)
Number of subjects: 40
Study 17374025 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention group (IG: n=39) attending regular nutrition education sessions for 5 months
Number of subjects: 75
Study 17374025 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG: n=36)
Number of subjects: 75
Study 14686965 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose, 150 mg/day
Number of subjects: 56
Study 14686965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 11829107 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) at a daily dose of 60 mg
Number of subjects: 10
Study 11829107 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA)
Number of subjects: 10
Study 11829107 — intervention group
Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (nCPAP)
Number of subjects: 10
Study 9503434 — intervention group
Group type: EXPERIMENTAL
Intervention: Convergence Insufficiency (CI) classification
Number of subjects: 620
Study 9503434 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms related to CI
Number of subjects: 620
Study 9229882 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous indomethacin 50 mg
Number of subjects: 20
Study 9229882 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2630362 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast Sensitivity Test (CST)
Number of subjects: 0
Study 2630362 — intervention group
Group type: COMPARATOR
Intervention: Electro-retinography (EOG)
Number of subjects: 0
Study 2630362 — intervention group
Group type: COMPARATOR
Intervention: Pattern Visual Evoked Potential (PVEP)
Number of subjects: 0
Study 776487 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 75 mg/day, increased to a maximum of 900 mg if tolerated
Number of subjects: 18
Study 776487 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol therapy after 8 weeks
Number of subjects: 18
Study 776487 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 18
Study 30958833 — intervention group
Group type: EXPERIMENTAL
Intervention: CARE4STROKE program (8-week caregiver-mediated exercise program with e-health support)
Number of subjects: 66
Study 30958833 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 66
Study 28643825 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant-supported removable partial denture with implants placed in the molar region
Number of subjects: 30
Study 28643825 — intervention group
Group type: COMPARATOR
Intervention: Implant-supported removable partial denture with implants placed in the pre-molar region
Number of subjects: 30
Study 28643825 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of treatment
Number of subjects: 30
Study 25682798 — intervention group
Group type: EXPERIMENTAL
Intervention: EHFP + MNP
Number of subjects: 335
Study 25682798 — intervention group
Group type: EXPERIMENTAL
Intervention: EHFP
Number of subjects: 335
Study 25682798 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 335
Study 23866979 — intervention group
Group type: EXPERIMENTAL
Intervention: dKC-50 (50% replacement of SBM)
Number of subjects: 18
Study 23866979 — intervention group
Group type: EXPERIMENTAL
Intervention: dKC-75 (75% replacement of SBM)
Number of subjects: 18
Study 23866979 — intervention group
Group type: COMPARATOR
Intervention: Control (0% replacement of SBM)
Number of subjects: 18
Study 21574446 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoflavin as a component of combined therapy
Number of subjects: 50
Study 19801054 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophilic catheters
Number of subjects: 56
Study 19801054 — intervention group
Group type: COMPARATOR
Intervention: Noncoated catheters (Control)
Number of subjects: 56
Study 16952987 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNF-alpha therapy
Number of subjects: 77
Study 16952987 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 77
Study 15242435 — intervention group
Group type: EXPERIMENTAL
Intervention: A-line AEP Monitor (AAI)
Number of subjects: 112
Study 15242435 — intervention group
Group type: EXPERIMENTAL
Intervention: End-expiratory sevoflurane concentration
Number of subjects: 112
Study 11275039 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta (3 million IU daily for 5 days, followed by 2 days of rest for 3 weeks)
Number of subjects: 61
Study 11275039 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 9467221 — intervention group
Group type: EXPERIMENTAL
Intervention: High P/S diet (P/S ratio of 1.67)
Number of subjects: 6
Study 9467221 — intervention group
Group type: COMPARATOR
Intervention: Low P/S diet (P/S ratio of 0.19)
Number of subjects: 6
Study 9467221 — intervention group
Group type: EXPERIMENTAL
Intervention: High P/S ratio breakfast
Number of subjects: 6
Study 8292640 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental condition: one monthly non‐random urine screen, one monthly counseling session, one monthly doctor visit, two times per month methadone pick up, a quarterly true random urine screen and participation in a diversion control program
Number of subjects: 130
Study 8292640 — intervention group
Group type: COMPARATOR
Intervention: Control condition: staying under standard conditions for six months and then being transferred to the experimental condition for six months
Number of subjects: 130
Study 2949920 — intervention group
Group type: EXPERIMENTAL
Intervention: Human ultralente insulin (0.30 U/kg)
Number of subjects: 6
Study 2949920 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcine ultralente insulin (0.30 U/kg)
Number of subjects: 6
Study 2949920 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine ultralente insulin (0.30 U/kg)
Number of subjects: 6
Study 2949920 — intervention group
Group type: COMPARATOR
Intervention: Diluent (control)
Number of subjects: 6
Study 29468229 — intervention group
Group type: EXPERIMENTAL
Intervention: Inletting energy of 7.5 eV
Number of subjects: 2000
Study 29468229 — intervention group
Group type: EXPERIMENTAL
Intervention: Inletting energy of 9 eV
Number of subjects: 2000
Study 29468229 — intervention group
Group type: EXPERIMENTAL
Intervention: Inletting energy of 12 eV
Number of subjects: 2000
Study 29468229 — intervention group
Group type: EXPERIMENTAL
Intervention: Inletting energy of 15 eV
Number of subjects: 2000
Study 29468229 — intervention group
Group type: EXPERIMENTAL
Intervention: Inletting energy range
Number of subjects: 2000
Study 29468229 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimum required inletting energy
Number of subjects: 2000
Study 27507134 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided e-learning intervention for managers
Number of subjects: 36
Study 27507134 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative research alongside the trial
Number of subjects: 36
Study 27507134 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative data
Number of subjects: 36
Study 25304725 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (angiotensin receptor blocker)
Number of subjects: 3014
Study 25304725 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (calcium channel blocker)
Number of subjects: 3014
Study 21432861 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobactin® (cyproheptadine + cobamamide)
Number of subjects: 0
Study 21432861 — intervention group
Group type: COMPARATOR
Intervention: Cobavital® (cyproheptadine + cobamamide)
Number of subjects: 0
Study 19425895 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA) for asymptomatic stenosis
Number of subjects: 0
Study 19425895 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA) for symptomatic stenosis
Number of subjects: 0
Study 19425895 — intervention group
Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 0
Study 17559152 — intervention group
Group type: EXPERIMENTAL
Intervention: PEGIFN alpha‐2b + WBR 13.3 mg/kg/day + EPO 40,000 U/week
Number of subjects: 150
Study 17559152 — intervention group
Group type: COMPARATOR
Intervention: PEGIFN alpha‐2b + WBR 13.3 mg/kg/day
Number of subjects: 150
Study 17559152 — intervention group
Group type: EXPERIMENTAL
Intervention: PEGIFN alpha‐2b + higher dose WBR 15.2 mg/kg/day + EPO
Number of subjects: 150
Study 15039008 — intervention group
Group type: EXPERIMENTAL
Intervention: SCP training (25 sessions within 3 weeks)
Number of subjects: 13
Study 15039008 — intervention group
Group type: EXPERIMENTAL
Intervention: SCP training
Number of subjects: 13
Study 15039008 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list group (Control)
Number of subjects: 13
Study 11678553 — intervention group
Group type: EXPERIMENTAL
Intervention: Single flexible sigmoidoscopy (FS) at around the age of 60 with removal of all small adenomas during FS and colonoscopy for 'high risk' polyps.
Number of subjects: 0
Study 11678553 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract).
Number of subjects: 0
Study 11678553 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable.
Number of subjects: 0
Study 9596245 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular stimulation
Number of subjects: 46
Study 9596245 — intervention group
Group type: COMPARATOR
Intervention: Placebo stimulation
Number of subjects: 46
Study 8150838 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue with thrombin
Number of subjects: 10
Study 8150838 — intervention group
Group type: COMPARATOR
Intervention: Placebo with thrombin
Number of subjects: 10
Study 3046385 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment
Number of subjects: 86
Study 3046385 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 7273929 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrostimulation test
Number of subjects: 100
Study 7273929 — intervention group
Group type: COMPARATOR
Intervention: No electrostimulation test (Control)
Number of subjects: 100
Study 30412416 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-3 week follow-up
Number of subjects: 344
Study 30412416 — intervention group
Group type: COMPARATOR
Intervention: 6-8 week follow-up
Number of subjects: 344
Study 28939589 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity (regardless of metabolic health)
Number of subjects: 21000
Study 28939589 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese and metabolically unhealthy
Number of subjects: 21000
Study 28939589 — intervention group
Group type: EXPERIMENTAL
Intervention: Women who had never used hormone therapy
Number of subjects: 21000
Study 25386711 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron treatment (500 mg)
Number of subjects: 15
Study 25386711 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 15
Study 23320499 — intervention group
Group type: EXPERIMENTAL
Intervention: Constipation-related symptoms assessment using the Knowles-Eccersley-Scott Symptom questionnaire
Number of subjects: 0
Study 23320499 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in anorectal angle and perineum descent during straining
Number of subjects: 0
Study 21183857 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous mannitol
Number of subjects: 60
Study 19583049 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed weighing on day 5
Number of subjects: 49
Study 19583049 — intervention group
Group type: COMPARATOR
Intervention: Standard care weighing on day 2 or 3
Number of subjects: 49
Study 17578353 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal intrauterine resuscitation using tocolysis and delayed delivery
Number of subjects: 390
Study 17578353 — intervention group
Group type: COMPARATOR
Intervention: Emergency delivery
Number of subjects: 390
Study 21213490 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 microg intravaginal misoprostol
Number of subjects: 50
Study 21213490 — intervention group
Group type: COMPARATOR
Intervention: 400 microg intravaginal misoprostol
Number of subjects: 50
Study 11784431 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ) therapy
Number of subjects: 291
Study 11784431 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (Fansidar) as replacement therapy
Number of subjects: 291
Study 9569340 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinded re-scrutiny of screening mammograms by two outside radiologists
Number of subjects: 544
Study 9569340 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval cancers
Number of subjects: 544
Study 9569340 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening programme design
Number of subjects: 544
Study 9569340 — intervention group
Group type: EXPERIMENTAL
Intervention: Age influence on interval cancer occurrence
Number of subjects: 544
Study 9569340 — intervention group
Group type: EXPERIMENTAL
Intervention: Criteria for referral for further investigation
Number of subjects: 544
Study 9569340 — intervention group
Group type: EXPERIMENTAL
Intervention: Efforts to reduce interval cancers
Number of subjects: 544
Study 8038847 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen insufflation during endotracheal suctioning
Number of subjects: 0
Study 8038847 — intervention group
Group type: COMPARATOR
Intervention: Hyperoxygenation protocol via ventilator
Number of subjects: 0
Study 2494397 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-generated message reminding the doctor to check blood pressure
Number of subjects: 8298
Study 2494397 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse contacted patients by telephone
Number of subjects: 8298
Study 2494397 — intervention group
Group type: EXPERIMENTAL
Intervention: Sending a letter to patients
Number of subjects: 8298
Study 2494397 — intervention group
Group type: COMPARATOR
Intervention: Normal-care control group
Number of subjects: 8298
Study 56146 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES) 500 ml during surgery and on the following three days
Number of subjects: 10
Study 56146 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline solution 500 ml during surgery and on the following three days
Number of subjects: 10
Study 31515821 — intervention group
Group type: EXPERIMENTAL
Intervention: Images taken by experienced cytologist
Number of subjects: 50
Study 31515821 — intervention group
Group type: EXPERIMENTAL
Intervention: Images taken by inexperienced cytologist
Number of subjects: 50
Study 31515821 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation of five images
Number of subjects: 50
Study 31515821 — intervention group
Group type: COMPARATOR
Intervention: Evaluation of two images
Number of subjects: 50
Study 28291842 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid remifentanil (0.15 μg/kg/min) administered intravenously for 60 minutes
Number of subjects: 14
Study 28291842 — intervention group
Group type: COMPARATOR
Intervention: Blindfolded condition
Number of subjects: 14
Study 28291842 — intervention group
Group type: COMPARATOR
Intervention: Eyes-open condition
Number of subjects: 14
Study 25874637 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task training (n=8), performed cognitive tasks simultaneously with balance training.
Number of subjects: 15
Study 25874637 — intervention group
Group type: COMPARATOR
Intervention: Single-task training (n=7), received balance training only.
Number of subjects: 15
Study 23065659 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute resistance exercise (3 sets, 10 repetitions at 60% 1RM)
Number of subjects: 13
Study 23065659 — intervention group
Group type: COMPARATOR
Intervention: Control session (30-min seated rest)
Number of subjects: 13
Study 21305572 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound examination of the sural nerve
Number of subjects: 100
Study 20027552 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterile water
Number of subjects: 44
Study 20027552 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline solution
Number of subjects: 44
Study 17172773 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 29
Study 17172773 — intervention group
Group type: COMPARATOR
Intervention: Crack information control condition
Number of subjects: 29
Study 15126714 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 g x kg NaHCO3
Number of subjects: 10
Study 15126714 — intervention group
Group type: COMPARATOR
Intervention: 0.207 g x kg NaCl (CON)
Number of subjects: 10
Study 11547222 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro
Number of subjects: 64
Study 11547222 — intervention group
Group type: COMPARATOR
Intervention: Regular human insulin
Number of subjects: 64
Study 9989324 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivationally‐matched, individually‐tailored intervention (IT)
Number of subjects: 194
Study 9989324 — intervention group
Group type: COMPARATOR
Intervention: Standard self‐help intervention (ST)
Number of subjects: 194
Study 9989324 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 194
Study 8160720 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium fiber (6.7 g daily)
Number of subjects: 42
Study 8160720 — intervention group
Group type: COMPARATOR
Intervention: Wheat bran control cereals
Number of subjects: 42
Study 2895801 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC (fluorouracil, cyclophosphamide, epirubicin)
Number of subjects: 263
Study 2895801 — intervention group
Group type: COMPARATOR
Intervention: FAC (fluorouracil, cyclophosphamide, doxorubicin)
Number of subjects: 263
Study 2895801 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC
Number of subjects: 263
Study 2895801 — intervention group
Group type: COMPARATOR
Intervention: FAC
Number of subjects: 263